The Week in Review: China’s 12th Five-year Plan for Medical Technology
China released its 12th Five-year Plan for Medical Technology, setting a long list of broad goals to be accomplished by the end of 2015; the World Health Organization certified the quality of the SFDA’s vaccine supervision, opening a huge market for vaccine makers; China wants to increase the benefits of its healthcare reform for citizens; Huahai Pharma will raise as much as $204 million through a private placement; Regeneron and Bayer have begun a China Phase III trial of their treatment for wet AMD; Ascletis was nominated for InVivo’s Exit/Financing Deal of the Year award; Sihuan Bioengineering is suing Vitapharm Technology of Australia over a patent dispute; Haibin Pharma received a EU-GMP certificate from Germany for meropenem bulk drug; and LDR was granted SFDA approval to market two spinal device systems. More details…. Stock Symbols: (SHA: 600521) (NSDQ: REGN) (XETRA: BAY) (SHE: 000518) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here